Lupus is a chronic autoimmune disorder characterised by an abnormal over activation of B cells. Credit: Nephron.

US-based biopharmaceutical company Provention Bio has reported positive data from the Phase Ib portion of the PREVAIL (PRV-3279 EVAluation In Lupus) study of PRV-3279 in healthy volunteers.

PRV-3279 is a humanised diabody targeting B-cell surface proteins CD32B and CD79B. It is developed for the interception of systemic lupus erythematosus (SLE), a chronic autoimmune disorder also known as lupus.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The double-blind, placebo-controlled, multiple ascending dose Phase Ib portion of the PREVAIL study found that PRV-3279 was well-tolerated in the subjects.

Pharmacokinetic parameters were stated generally dose-proportional. The high levels of B-cell engagement resulted in durable pharmacodynamic responses in the study, which enrolled 16 healthy volunteers.

Provention Bio co-founder and chief scientific officer Francisco Leon said: “These results build on prior clinical data with PRV-3279 and existing evidence of the role of CD32B in lupus. These data further increase our enthusiasm for this potentially groundbreaking treatment of B-cell driven immunologic conditions with high unmet need, such as lupus.”

The company is planning to begin the Phase IIa portion of the PREVAIL study in the first half next year. The study, which will analyse the drug in lupus patients, will be based on the results from the current trial.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

These Phase Ib results are also expected to support a second development pathway for the prevention of immunogenicity of biotherapeutics such as gene therapy products.

SLE causes inflammation, tissue injury and damage in nearly every organ.

Provention Bio dosed the first patients in its Phase Ib/IIa PREVAIL clinical trial of humanised diabody PRV-3279 in August last year.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
YPrime won the Innovation award for AI in Clinical Trials and the Environmental award for Sustainable Trials, thanks to its eCOA, IRT and eConsent platforms. Explore how purpose-built AI, paperless workflows and circular hardware practices are reshaping timelines, data quality and ESG performance in clinical research.

Discover the Impact